Is the ACHN pipeline complementary rather than competitive with GILD/BMY?
Thx, DAV1234, good article. From it, I conclude a qualified 'yes,' to my question, the qualification being that the GILD/BMY nuke and others are considered preferable to ACHN's protease inhibitors because the latter aren't viewed as likely to stand on their own without the aid of injectable, side-effect-burdened, interferon.
Market Data 
Markets 
AI
